DYRK1A: a potential drug target for multiple down syndrome neuropathologies

Down syndrome

Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964 · see citing works

Down syndrome and the complexity of genome dosage imbalance

Antonarakis, S. (2016) · Nature reviews genetics · doi:10.1038/nrg.2016.154 · Cited by 264 · see citing works

Down syndrome and Alzheimer's disease: common pathways, common goals

Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290 · see citing works

Human Models Are Needed for Studying Human Neurodevelopmental Disorders

Zhao, X., & Bhattacharyya, A. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.10.009 · Cited by 192 · see citing works

The Down syndrome-related protein kinase DYRK1A phosphorylates p27^Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation

Soppa, U., Schumacher, J., Florencio Ortiz, V., Pasqualon, T., Tejedor, F., & Becker, W. (2014) · Cell Cycle · doi:10.4161/cc.29104 · Cited by 189 · see citing works

DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome

Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181 · see citing works

Mouse models of Down syndrome: gene content and consequences

Gupta, M., Dhanasekaran, A. R., & Gardiner, K. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9661-8 · Cited by 167 · see citing works

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

Abbassi, R. H., Johns, T. G., Kassiou, M., & Munoz, L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.03.004 · Cited by 156 · see citing works

Universal Alternative Splicing of Noncoding Exons

Deveson, I. W., Brunck, M. E. G., Blackburn, J., Tseng, E., Hon, T., Clark, T. A., Clark, M. B., Crawford, J., Dinger, M. E., Nielsen, L. K., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.005 · Cited by 151 · see citing works

Polyphenols and neuroprotection: therapeutic implications for cognitive decline

Caruso, G., Torrisi, S. A., Mogavero, M. P., Currenti, W., Castellano, S., Godos, J., Ferri, R., Galvano, F., Leggio, G. M., Grosso, G., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108013 · Cited by 140 · see citing works

Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview

Lindberg, M. F., & Meijer, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116047 · Cited by 123 · see citing works

A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

Coutadeur, S., Benyamine, H., Delalonde, L., de Oliveira, C., Leblond, B., Foucourt, A., Besson, T., Casagrande, A.-S., Taverne, T., Girard, A., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.13018 · Cited by 121 · see citing works

DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis

Fernández, P., Zahonero, C., & Sánchez‐Gómez, P. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.970048 · Cited by 110 · see citing works

10-Iodo-11 H -indolo[3,2- c ]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A

Falke, H., Chaikuad, A., Becker, A., Loaëc, N., Lozach, O., Jhaisha, S. A., Becker, W. B., Jones, P. G., Preu, L., Baumann, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501994d · Cited by 109 · see citing works

Down syndrome: Neurobiological alterations and therapeutic targets

Vacca, R. A., Bawari, S., Valenti, D., Tewari, D., Nabavi, S. F., Shirooie, S., Sah, A. N., Volpicella, M., Braidy, N., & Nabavi, S. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.01.001 · Cited by 90 · see citing works

GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways

Demuro, S., Martino, R. M. C. D., Ortega, J. A., & Cavalli, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169098 · Cited by 85 · see citing works

Dyrk1A Inhibition as Potential Treatment for Alzheimer’S Disease

Stotani, S., Giordanetto, F., & Medda, F. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0013 · Cited by 78 · see citing works

Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome

Stagni, F., Giacomini, A., Emili, M., Trazzi, S., Guidi, S., Sassi, M., Ciani, E., Rimondini, R., & Bartesaghi, R. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.07.031 · Cited by 76 · see citing works

Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation

Kumar, K., Wang, P., Sánchez, R., Swartz, E., Stewart, A. F., & DeVita, R. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00658 · Cited by 77 · see citing works

Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

Melchior, B., Mittapalli, G. K., Lai, C., Duong‐Polk, K., Stewart, J., Güner, B., Hofilena, B. J., Tjitro, A., Anderson, S., Herman, D. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13000 · Cited by 73 · see citing works

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature

Nguyen, T. L., Fruit, C., Hérault, Y., Meijer, L., & Besson, T. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1360285 · Cited by 67 · see citing works

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors

Rüben, K., Wurzlbauer, A., Walte, A., Sippl, W., Bracher, F., & Becker, W. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132453 · Cited by 65 · see citing works

Influence of prenatal EGCG treatment andDyrk1adosage reduction on craniofacial features associated with Down syndrome

McElyea, S. D., Starbuck, J. M., Tumbleson, D. M., Harrington, E., Blazek, J. D., Ghoneima, A. A. M., Kula, K. S., & Roper, R. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw309 · Cited by 59 · see citing works

Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor

Kumar, K., Wang, P., Wilson, J., Zlatanic, V., Berrouet, C. C., Khamrui, S., Secor, C., Swartz, E., Lazarus, M. B., Sánchez, R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01379 · Cited by 60 · see citing works

Synthesis and molecular modelling studies of 8-arylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors

Loidreau, Y., Deau, E., Marchand, P., Nourrisson, M., Logé, C., Coadou, G., Loaëc, N., Meijer, L., & Besson, T. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.038 · Cited by 58 · see citing works

Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules

Rothweiler, U., Stensen, W., Brandsdal, B. O., Isaksson, J. M., Leeson, F., Engh, R. A., & Svendsen, J. S. M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01086 · Cited by 50 · see citing works

Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies

Tarpley, M., Oladapo, H. O., Strepay, D., Caligan, T. B., Chdid, L., Shehata, H., Roques, J., Thomas, R., Laudeman, C. P., Onyenwoke, R. U., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105821 · Cited by 48 · see citing works

Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II

Foucourt, A., Hédou, D., Dubouilh‐Benard, C., Girard, A., Taverne, T., Casagrande, A.-S., Désiré, L., Leblond, B., & Besson, T. (2014) · Molecules · doi:10.3390/molecules191015411 · Cited by 49 · see citing works

Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome

Catuara‐Solarz, S., Espinosa‐Carrasco, J., Erb, I., Langohr, K., Notredame, C., González, J. R., & Dierssen, M. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00330 · Cited by 44 · see citing works

Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity

Kumar, K., Ung, P. M. U., Wang, P., Wang, H., Li, H., Andrews, M. K., Stewart, A. F., Schlessinger, A., & DeVita, R. J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.007 · Cited by 47 · see citing works

An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases

Chaikuad, A., Diharce, J., Schröder, M., Foucourt, A., Leblond, B., Casagrande, A.-S., Désiré, L., Bonnet, P., Knapp, S., & Besson, T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01083 · Cited by 46 · see citing works

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

Stringer, M., Goodlett, C. R., & Roper, R. J. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.334 · Cited by 44 · see citing works

Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases

Correa-Sáez, A., Jiménez‐Izquierdo, R., Garrido‐Rodríguez, M., Morrugares, R., Muñóz, E., & Calzado, M. A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03556-1 · Cited by 45 · see citing works

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model

Stringer, M., Abeysekera, I., Dria, K. J., Roper, R. J., & Goodlett, C. R. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.09.002 · Cited by 45 · see citing works

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

Arranz, J., Balducci, E., Arató, K., Sánchez‐Elexpuru, G., Najas, S., Parras, A., Rebollo, E., Pijuan, I., Erb, I., Verde, G., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.022 · Cited by 40 · see citing works

The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A–PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine

Alexeeva, M., Åberg, E., Engh, R. A., & Rothweiler, U. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715005106 · Cited by 38 · see citing works

Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A

Kay, L. J., Smulders-Srinivasan, T. K., & Soundararajan, M. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.07.001 · Cited by 38 · see citing works

Modeling Down syndrome in animals from the early stage to the 4.0 models and next

Moreno, M. D. M. M., Brault, V., Birling, M., Pavlovic, G., & Hérault, Y. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2019.08.001 · Cited by 32 · see citing works

Dose imbalance of DYRK1A kinase causes systemic progeroid status in Down syndrome by increasing the un-repaired DNA damage and reducing LaminB1 levels

Murray, A., Gough, G., Cindrić, A., Vučković, F., Koschut, D., Borelli, V., Petrović, D. J., Bekavac, A., Plećaš, A., Hribljan, V., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104692 · Cited by 37 · see citing works

Advances in tetrahydropyrido[1,2- a ]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors

Boulahjar, R., Ouach, A., Bourg, S., Bonnet, P., Lozach, O., Meijer, L., Guguen‐Guillouzo, C., Guével, R. L., Lazar, S., Mohamed Akssira, A., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.046 · Cited by 35 · see citing works

Alkaloids as Potential Multi-Target Drugs to Treat Alzheimer's Disease

Lima, J. A., & Hamerski, L. (2018) · Studies in natural products chemistry · doi:10.1016/b978-0-444-64183-0.00008-7 · Cited by 34 · see citing works

Structure–Activity Relationship in the Leucettine Family of Kinase Inhibitors

Tahtouh, T., Durieu, É., Villiers, B., Bruyère, C., Nguyen, T. L., Fant, X., Ahn, K. H., Khurana, L., Deau, E., Lindberg, M. F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01141 · Cited by 31 · see citing works

Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design

Meine, R., Becker, W. B., Falke, H., Preu, L., Loaëc, N., Meijer, L., & Kunick, C. (2018) · Molecules · doi:10.3390/molecules23020064 · Cited by 32 · see citing works

Development of novel 2,4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives

Darwish, S. S., Abdel‐Halim, M., Salah, M., Abadi, A., Becker, W. B., & Engel, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.050 · Cited by 28 · see citing works

Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions

Murphy, A. J., Wilton, S. D., Aung-Htut, M. T., & McIntosh, C. S. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1391564 · Cited by 27 · see citing works

Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2

Mariano, M., Hartmann, R. W., & Engel, M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.017 · Cited by 27 · see citing works

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

Walter, A., Chaikuad, A., Helmer, R., Loaëc, N., Preu, L., Ott, I., Knapp, S., Meijer, L., & Kunick, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196761 · Cited by 27 · see citing works

Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification

Darwish, S. S., Abdel‐Halim, M., ElHady, A. K., Salah, M., Abadi, A., Becker, W. B., & Engel, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.097 · Cited by 26 · see citing works

Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus

Grannò, S., Nixon‐Abell, J., Berwick, D. C., Tosh, J., Heaton, G., Almudimeegh, S., Nagda, Z., Rain, J., Zanda, M., Plagnol, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43820-4 · Cited by 25 · see citing works

[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors

Lechner, C., Flaßhoff, M., Falke, H., Preu, L., Loaëc, N., Meijer, L., Knapp, S., Chaikuad, A., & Kunick, C. (2019) · Molecules · doi:10.3390/molecules24224090 · Cited by 24 · see citing works

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome

Stensen, W., Rothweiler, U., Engh, R. A., Stasko, M. R., Bederman, I. R., Costa, A. C. S., Fugelli, A., & Svendsen, J. S. M. (2021) · Pharmaceuticals · doi:10.3390/ph14111170 · Cited by 22 · see citing works

Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models

Raza, J., LaCombe, J., Patel, R., Blackwell, M. P., Thomas, J. R., Sloan, K., Wallace, J. M., & Roper, R. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264254 · Cited by 18 · see citing works

Structure–Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation

Kumar, K., Wang, P., Swartz, E., Khamrui, S., Secor, C., Lazarus, M. B., Sánchez, R., Stewart, A. F., & DeVita, R. J. (2020) · Molecules · doi:10.3390/molecules25081983 · Cited by 21 · see citing works

Minibrain drives the Dacapo dependent cell cycle exit of neurons in the Drosophila brain by promoting asense and prospero expression

Nurunnabi, S. M., Gutiérrez-Aviñó, F. J., Colonques, J., Cerón, J., Hämmerle, B., & Tejedor, F. J. (2016) · Development · doi:10.1242/dev.134338 · Cited by 20 · see citing works

DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B

Yousefelahiyeh, M., Xu, J., Alvarado, E., Yang, Y., Salven, D. S., & Nissen, R. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207779 · Cited by 19 · see citing works

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18 · see citing works

Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases

Hédou, D., Godeau, J., Loaëc, N., Meijer, L., Fruit, C., & Besson, T. (2016) · Molecules · doi:10.3390/molecules21050578 · Cited by 18 · see citing works

Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome?

Stagni, F., Giacomini, A., Emili, M., Guidi, S., Ciani, E., & Bartesaghi, R. (2017) · Neurogenesis · doi:10.1080/23262133.2016.1270383 · Cited by 17 · see citing works

Recent research and development of DYRK1A inhibitors

Zhao, L., Xiong, X., Liu, L., Liang, Q., Tong, R., Feng, X., Bai, L., & Shi, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.10.003 · Cited by 16 · see citing works

The Role of Oxidative Stress in Trisomy 21 Phenotype

Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., & Zbucka-Krętowska, M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01417-6 · Cited by 18 · see citing works

Age exacerbates abnormal protein expression in a mouse model of Down syndrome

Ahmed, M. M., Block, A., Tong, S., Davisson, M. T., & Gardiner, K. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.002 · Cited by 16 · see citing works

Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A

Miyazaki, Y., Kikuchi, M., Umezawa, K., Descamps, A., Nakamura, D., Furuie, G., Sumida, T., Saito, K., Kimura, N., Niwa, T., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113948 · Cited by 14 · see citing works

Improving Memory and Cognition in Individuals with Down Syndrome

Rafii, M. S. (2016) · CNS Drugs · doi:10.1007/s40263-016-0353-4 · Cited by 14 · see citing works

How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition—The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine

Wurzlbauer, A., Rüben, K., Gürdal, E. E., Chaikuad, A., Knapp, S., Sippl, W., Becker, W. B., & Bracher, F. (2020) · Molecules · doi:10.3390/molecules25245962 · Cited by 13 · see citing works

Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome

Long, R., Drawbaugh, M. L., Davis, C., Goodlett, C. R., Williams, J., & Roper, R. J. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.07.002 · Cited by 13 · see citing works

Importance of gene dosage in controlling dendritic arbor formation during development

Copf, T. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.13002 · Cited by 12 · see citing works

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model

Hawley, L. E., Stringer, M., Deal, A. J., Folz, A., Goodlett, C. R., & Roper, R. J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106359 · Cited by 10 · see citing works

Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model

LaCombe, J., Sloan, K., Thomas, J. R., Blackwell, M. P., Crawford, I., Bishop, F., Wallace, J. M., & Roper, R. J. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050914 · Cited by 9 · see citing works

Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome

Çağlayan, E. (2016) · Cell Biology International · doi:10.1002/cbin.10694 · Cited by 7 · see citing works

Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B

Segretti, N., Takarada, J. E., Ferreira, M. A., Santiago, A. D. S., Teodoro, B. V. M., Damião, M. C. F. C. B., Godoi, P. H., Cunha, M. R., Fala, A. M., Ramos, P. Z., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128764 · Cited by 7 · see citing works

Embryonic organizer formation disorder leads to multiorgan dysplasia in Down syndrome

Liu, Y., Lin, Z., Peng, Y., Jiang, Y., Zhang, X., Zhu, H., Zhang, L., Chen, J., Shu, X., Luo, M., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05517-x · Cited by 6 · see citing works

In-silico study for African plants with possible beta-cell regeneration effect through inhibition of DYRK1A

Chikodili, I., Chioma, I., Chinwendu, N., & IfedibaluChukwu, E. (2022) · Sciences of Phytochemistry · doi:10.58920/sciphy01010013 · Cited by 6 · see citing works

The role of Goldilocks protein kinase DYRK1A in embryonic development

Johnson, H. K., Litovchick, L., & DICKINSON, A. J. G. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2025.06.009 · Cited by 5 · see citing works

A Researcher’s guide to rodent models of Down syndrome: Recent insights and translational perspectives

Raza, M. A., Folz, A., Victorino, D. B., Xing, Z., Chen, X., Zuo, X., Borden, L. K., Potier, M., Mobley, W. C., Dierssen, M., et al. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104717 · Cited by 5 · see citing works

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2024) · eLife · doi:10.7554/elife.89763.3 · Cited by 5 · see citing works

Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations

Li, J. J., Tian, Y. L., Zhai, H. L., Lv, M., & Zhang, X. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25056 · Cited by 5 · see citing works

Can Green Tea Polyphenols Improve Phenotypes Associated With Down Syndrome?

Roper, R. J., & Goodlett, C. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813008-7.00035-7 · Cited by 5 · see citing works

STRUCTURE AND STEREOCHEMISTRY OF A HYDRAZONE DERIVATIVE OF HARMINE

Аманжан, А., Zhanymkhanova, P. Z., Bagryanskaya, I. Y., Shults, E. E., Турмухамбетов, А. Ж., & Adekenov, S. M. (2021) · Journal of Structural Chemistry · doi:10.1134/s0022476621030161 · Cited by 5 · see citing works

An ELISA DYRK1A non-radioactive kinase assay suitable for the characterization of inhibitors

Liu, Y., Adayev, T., & Hwang, Y. (2017) · F1000Research · doi:10.12688/f1000research.10582.2 · Cited by 5 · see citing works

An ELISA DYRK1A non-radioactive assay suitable for the characterization of inhibitors

Liu, Y., Adayev, T., & Hwang, Y. (2017) · F1000Research · doi:10.12688/f1000research.10582.1 · Cited by 4 · see citing works

Sex specific emergence of trisomic Dyrk1a -related skeletal phenotypes in the development of a Down syndrome mouse modelPreprint

LaCombe, J., Sloan, K., Thomas, J. R., Blackwell, M. P., Crawford, I., Wallace, J. M., & Roper, R. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.24.595804 · Cited by 4 · see citing works

Identification and Validation of an Inhibitor of the Protein Kinases PIM and DYRK

Bencze, G., Venkataramani, P., Elkayam, E., Rivera, K. D., Garg, A., Szabadakai, I., Őrfi, L., Joshua‐Tor, L., Pappin, D., & Tonks, N. K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03226 · Cited by 3 · see citing works

A cluster of protein kinases and phosphatases modulated in fetal Down syndrome (trisomy 21) brain

Weitzdoerfer, R., Torán, N., Subramaniyan, S., Pollak, A. J., Dierssen, M., & Lübec, G. (2015) · Amino Acids · doi:10.1007/s00726-015-1941-1 · Cited by 3 · see citing works

In-silico Study for African Plants with Possible Beta-Cell Regeneration Effect through Inhibition of DYRK1A

IfedibaluChukwu, E. I. (2022) · Open Access Journal of Pharmaceutical Research · doi:10.23880/oajpr-16000270 · Cited by 3 · see citing works

Clinical trials for Alzheimer's disease in Down syndrome

Rafii, M. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00017-7 · Cited by 2 · see citing works

Dyrk1a

Tejedor, F. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101613 · Cited by 2 · see citing works

The Genetic Dosage Imbalance Linked to Clinical Brain Alterations and Mental Disability in Down Syndrome Could be Targeted for Therapeutics Development

Rachidi, M. (2018) · Medical Journal of Clinical Trials & Case Studies · doi:10.23880/mjccs-16000150 · Cited by 1 · see citing works

Epigallocatechin-3-gallate

Stagni, F., Guidi, S., & Bartesaghi, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817986-4.00053-5 · Cited by 1 · see citing works

The Dual-Specificity Tyrosine Phosphorylation Regulated Kinase 1A and the Advances of Its Inhibitors

王, 勇. (2020) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2020.82006 · Cited by 1 · see citing works

Virtual screening of small molecules for targeting DYRK1A kinase: Identifying novel inhibitors through computational approaches

Ursal, K. D., & Kar, P. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100038 · Cited by 1 · see citing works

Identification de biomarqueurs sanguins chez des sujets à risque pour la maladie d’Alzheimer

Potier, M. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.02.003 · Cited by 1 · see citing works

Dyrk1a

Tejedor, F. J. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101613-1 · Cited by 1 · see citing works

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2023) · eLife · doi:10.1101/2023.07.31.551282 · Cited by 6 · see citing works

Les déficits cognitifs dans la trisomie 21, de la naissance à la démence : mécanismes et traitements

Potier, M. (2016) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30567-9

Faculty Opinions recommendation of Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.

Reeves, R. H. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736421494.793563938

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse modelPreprint

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2023) · eLife · doi:10.7554/elife.89763.1

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse modelPreprint

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2024) · eLife · doi:10.7554/elife.89763.2

Conception et synthèse d’inhibiteurs duaux de DYRK1A et CLK1, kinases impliquées dans la maladie d’Alzheimer

Pescheteau, C. (2021) · doi:10.70675/f258c770z5a4bz407bz9533z56a9b2b6a0f8

LONG-TERM NEURODEVELOPMENTAL AND COGNITIVE OUTCOMES FOLLOWING PRENATAL INHIBITION OF DYRK1A BY LEUCETTINE L41 IN MOUSE MODELS OF DOWN SYNDROMEPreprint

Duchon, A., Chevalier, C., Gizzi, P., Dairou, J., & Hérault, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724917

DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome

Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181 · see citing works

The MNB/DYRK1A protein kinase: Neurobiological functions and Down syndrome implications

Hämmerle, B., Elizalde, C., Galcerán, J., Becker, W. B., & Tejedor, F. J. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6721-2_11 · Cited by 81 · see citing works

Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase‐1A (DYRK1A), A Master Regulatory Protein Involved in Down Syndrome Brain Alterations and Mental Disability, A Key Contributor to Neurodegenerative Disorders of Alzheimer's Disease and A Potential Therapeutic Target

Rachidi, M. (2022) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710023

Recent insights into the function of DYRK1A

Becker, W. B. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07953.x · Cited by 10 · see citing works

DYRK1A (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A), a Master Regulatory Protein Involved in Down Syndrome Clinical Neurological Abnormalities and Associated Mental Retardation and a Promising Potential Drug Target for Therapeutics and Treatments

Rachidi, M. (2023) · Medical Journal of Clinical Trials & Case Studies · doi:10.23880/mjccs-16000347